ストックスクリーナーアプリを入手
17.80
3.10%
-0.57
アフターアワーズ：
17.80
前日終値:
$18.37
開ける：
$18.08
24時間の取引高:
1.02M
Relative Volume:
1.24
時価総額：
$1.18B
収益：
$9.98M
当期純損益:
$-154.08M
株価収益率:
-6.8992
EPS:
-2.58
ネットキャッシュフロー:
$-159.66M
1週間 パフォーマンス:
+8.47%
1か月 パフォーマンス:
-12.83%
6か月 パフォーマンス:
-40.11%
1年 パフォーマンス:
-53.89%
1日の値動き範囲:
$17.45
$18.13
1週間の範囲:
$15.39
$18.53
52週間の値動き範囲:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
CLDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
17.80 | 1.18B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com
Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia
Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Detailed In New Research Report - openPR.com
Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq
Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines
Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa
Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com
Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews
Why Celldex Deserves Your Attention? - RTTNews
Charles Schwab Investment Management Inc. Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
7 Analysts Have This To Say About Celldex Therapeutics - Benzinga
Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq
MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView
Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - MarketScreener
Personalized Cancer Vaccines Market | Growth, Innovations & - openPR
Strategies for Managing Chronic Spontaneous Urticaria - Medscape
Celldex Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
A better buy-in window may exist right now for Celldex Therapeutics Inc (CLDX) - SETE News
Comparing Oruka Therapeutics (NASDAQ:ORKA) & Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Celldex Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
The Goldman Sachs Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - Armenian Reporter
Celldex’s CDX-622 shows promise for inflammatory disorders - BioWorld Online
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
CLDXCelldex Therapeutics Inc Latest Stock News & Market Updates - StockTitan
H.C. WAINWRIGHT MAINTAINS BUY RATING, $80 TARGET ON CELLDEX STOCK - Investing.com UK
Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group - Defense World
UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN
Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug - Nasdaq
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - The Manila Times
Can Celldex's Dual-Mechanism CDX-622 Transform Inflammatory Disease Treatment? - StockTitan
Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright - Defense World
Celldex announces data from Phase 2 barzolvolimab studies - MSN
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - The Manila Times
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - The Manila Times
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients ... - Enid News & Eagle
Can Celldex's Urticaria Treatment Transform Patient Lives? Phase 2 Data Shows 95% Quality of Life Improvement - StockTitan
Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright - MarketBeat
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Celldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics - Benzinga
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex: Q4 Earnings Snapshot - The Washington Post
Celldex Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.22%
大文字化:
|
ボリューム (24 時間):